• 3003新葡的京集团

    集团群站
    • 天道医药中国
    • 天道医药英国
    • 天道医药波兰
    • 天道医药意大利
    • 天道医药西班牙
    • 天道医药德国
    • 天道医药美国
    • 赛湾生物
    • SPL

    更用心，只为更好地护佑健康

    我们将对患者的关怀体现在药物生产和运转的全过程细节把控中
    Inhixa
    通用名：
    依诺肝素钠注射液
    销售市场：
    欧盟非波兰
    规格：
    2,000 IU (20 mg)/0.2 mL 4,000 IU (40 mg)/0.4 mL 6,000 IU (60 mg)/0.6 mL 8,000 IU (80 mg)/0.8 mL 10,000 IU (100 mg)/1.0 mL 12,000 IU (120 mg)/0.8 mL 15,000 IU (150 mg)/1 mL 30,000 IU (300 mg)/3 mL 50,000 IU (500 mg)/5 mL 100,000 IU (1000 mg)/10 mL
    适应症：
    Inhixa is indicated in adults for:

    ·Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.

    ·Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.

    ·Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.

    ·Prevention of thrombus formation in extra corporeal circulation during haemodialysis.

    ·Acute coronary syndrome:

    ·Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.

    ·Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).